Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Retrotransposon Gag-like protein 4 (RTL4) is a protein encoded by the RTL4 gene in humans. It is a member of the Mar/Mart family of retrotransposon-derived genes, related to long terminal repeat retrotransposons, but does not correspond to an active transposable element. RTL4 is predicted to bind nucleic acids and zinc ions, and may play a role in cognitive function in the brain through pathways involving the noradrenergic system. Its main molecular characteristics include a zinc finger CCHC domain, which is typically involved in nucleic acid binding. Mutations or dysfunction of RTL4 have been associated with Inflammatory Bowel Disease 30, but the gene is not considered a validated therapeutic target. There are no known drugs or specific biomarkers for RTL4 at this time, and its safety or therapeutic profile is not established in clinical contexts
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retrotransposon Gag-like protein 4 (RTL4).